Core Insights - WuXi AppTec reported strong financial performance for the first three quarters of 2025, with revenue reaching 32.857 billion yuan, a year-on-year increase of 18.61% [1] - The company’s net profit attributable to shareholders was 9.522 billion yuan, reflecting a significant growth of 42.51% year-on-year [1] - The company’s cash flow from operations for the first three quarters was 10.87 billion yuan, up 35% compared to the previous year [1] Business Segment Performance - Revenue from the chemical business segment was 25.978 billion yuan, showing a robust year-on-year growth of 29.28%, making it the fastest-growing segment [1] - The testing business generated 4.169 billion yuan, while the biological business and other segments contributed 1.947 billion yuan and 0.352 billion yuan, respectively [1] Order Backlog and Future Guidance - As of September 30, 2025, the company’s order backlog reached 59.9 billion yuan, marking a 41.2% increase year-on-year [1] - The company has raised its revenue growth forecast for 2025 from 13%-17% to 17%-18%, with total revenue expectations adjusted from 42.5 billion to 44 billion yuan [1][2] - Free cash flow guidance for the year has been increased from 5-6 billion yuan to 8-8.5 billion yuan [1] Strategic Focus - WuXi AppTec announced the sale of its 100% stake in the Chinese clinical service research business for a base price of 2.8 billion yuan, allowing the company to concentrate on its CRDMO business model [2] - The CEO emphasized that the company will focus on drug discovery, laboratory testing, and process development and production services, enhancing its global capabilities and capacity [3]